Rising incidence of investment in biomarkers for drug development is the major factor influencing market growth.
Market Size – USD 18.23 billion in 2018, Market Growth - CAGR of 4.6%, Market Trends –Rise in advanced diagnostics for early detection, along with more specific drug development, and emerging innovative diagnostics technologies.
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- The Alzheimer’s Therapeutics Market is expected to reach USD 12.43 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the growing pipeline drug development, investment in biomarkers for drug development which are expected to further accelerate the market growth globally. Based on statistics, increase in advanced diagnostics for early detection, along with more specific drug development, and emerging innovative diagnostics technologies are also some of the factors that are also helping to grow the size of the global market.
Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/1364
Alzheimer's disease (AD) is the most usual cause of dementia worldwide. The study of this disease is multifactorial, and pathophysiology is also complicated. According to several types of research, an exponential rise in the number of cases of AD, highlighting the need for developing an effective treatment. AD also imposes a tremendous emotional and financial trouble to the patient's family and society. The disease has been studied for more than a century, but memantine and acetylcholinesterase inhibitors are the only drugs currently recommended for its management. These drugs provide significant improvement alone but do less to change the disease process. The significant penetration into the molecular and cellular pathomechanism in AD over the previous few decades has given us considerable progress in the understanding of the disease. Several novel strategies that seek to revise the disease process have been developed. The notable developments in this direction are the tau-based and amyloid therapeutics, which could hold the key to treatment of AD shortly.
North America market for Alzheimer’s Therapeutics accounts for the largest share of 29.30% in 2018. Due to the presence of advanced healthcare facilities and infrastructure in developed countries, such as the U.S. Moreover, the high buying power for expensive drugs and compensation policies are the drivers projected to promote the market demand.
Further key findings from the report suggest
To identify the key trends in the industry, click on the link below:
Segments covered in the report:
For the purpose of this study, Reports and Data have segmented the global Alzheimer’s Therapeutics Market on the basis of Therapeutics, End-User, Diagnostics Type and Region:
Therapeutics Outlook (Revenue, USD Million; 2016-2026)
End User Outlook (Revenue, USD Million; 2016-2026)
Diagnostics Type Outlook (Revenue, USD Million; 2016-2026)
Regional Outlook (Volume, Kilo Tons; Revenue, USD Billion; 2018-2026)
Browse more reports of Pharmaceutical category at: https://www.reportsanddata.com/report/category/pharmaceutical
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-800-819-3052